The case for low-level BACE1 inhibition for the prevention of Alzheimer disease

Nature Reviews Neurology, Published online: 21 September 2021; doi:10.1038/s41582-021-00545-1To date, all phase III trials of β-site amyloid precursor protein (APP)-cleaving enzyme (BACE) inhibitors for Alzheimer disease were either discontinued or produced negative results. Here the authors present their opinion that BACE inhibitors still hold promise as a preventative therapy for Alzheimer disease and outline a series of experiments to inform future trials.

Source: Nature Reviews Neurology - September 21, 2021 Category: Neurology Authors: Eric McDade Iryna Voytyuk Paul Aisen Randall J. Bateman Maria C. Carrillo Bart De Strooper Christian Haass Eric M. Reiman Reisa Sperling Pierre N. Tariot Riqiang Yan Colin L. Masters Robert Vassar Stefan F. Lichtenthaler Source Type: research